The Hanz-LNP technology platform can provide customized support based on different needs, including basic research, drug screening, and the development of cutting-edge therapies, to accelerate the implementation of research results, their transformation and application, as well as drug development.

Liver and extrahepatic delivery platforms
The traditional LNP technology mainly focuses on liver delivery, which limits its application in the treatment of non-liver-targeted diseases. Hanz Bio's extracorporeal delivery platform, through its independently patented LNP technology, achieves efficient targeted delivery to non-liver tissues such as the spleen, lungs, skin, and immune cells. This platform has demonstrated excellent performance in multiple in vivo validations of RNA types (mRNA, siRNA, circRNA) and gene editing tools, and is an ideal tool for exploring the mechanisms of non-liver diseases and developing new therapies.

Gene editing platform
Based on the LNP system with high encapsulation rate, high expression efficiency and low toxicity, Hanz Bio has developed a delivery platform specifically designed for delivering gene editing tools such as CRISPR/Cas9, Cas12, and base editor. This platform is compatible with various forms including mRNA + sgRNA and RNP, and can meet the needs of both in vitro and in vivo experiments. It is widely applicable to cell line construction, animal model construction, and the development of new treatment strategies, helping researchers complete gene operations precisely and efficiently.
Conjugation platform
This platform combines the targeting capabilities of LNP and antibodies, and adopts a chemical connection strategy to achieve efficient coupling of antibodies and LNP, enhancing the active targeting ability of LNP to specific cells or tissues. Through the conjugation of antibody-LNP complexes, the platform can precisely deliver to target points such as tumor cells and specific immune cells, significantly improving the therapeutic selectivity and safety, and providing support for the development of more targeted RNA drugs and immunotherapy schemes.

isCAR-T platform

The isCAR-T (in spleen CAR-T) platform utilizes an efficient LNP system to directly deliver mRNA encoding the CAR structure to the T cells in the body, enabling in-situ engineering of T cells (without the need for in vitro cultivation and reinfusion). This is an innovative approach that fundamentally changes the traditional CAR-T treatment process. The platform has advantages such as precise delivery, strong expression, and rapid intervention, reducing treatment costs and operational complexity. It is expected to accelerate the popularization of CAR-T therapy and expand its indication range.